Pricing
  1. US-listed companies
  2. CymaBay Therapeutics, Inc.
  3. Financials
  4. Net income

CymaBay Therapeutics, Inc. (CBAY)

Market cap
$3.7B
P/E ratio
SummaryFinancials
Period EndNet income (Million USD)YoY (%)
Dec 31, 2023-105-0.60%
Dec 31, 2022-106+17.78%
Dec 31, 2021-90+76.52%
Dec 31, 2020-51-50.40%
Dec 31, 2019-103+41.70%
Dec 31, 2018-73+163.27%
Dec 31, 2017-28+3.32%
Dec 31, 2016-27+71.75%
Dec 31, 2015-16-51.35%
Dec 31, 2014-32+216.86%
Dec 31, 2013-10

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat